Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. patient support
Show results for
Products
Services
Software
Training
Applications

Companies

News
Articles
Downloads
Videos

Refine by
Date

  • This month
  • This Year
  • Older

Patient Support Articles & Analysis

207 news found

RTsafe’s PseudoPatient Receives Saudi FDA Authorization, Expanding Access to Advanced Radiotherapy QA Across the Kingdom

RTsafe’s PseudoPatient Receives Saudi FDA Authorization, Expanding Access to Advanced Radiotherapy QA Across the Kingdom

According to the official SFDA authorization document, RTsafe is authorized to market its patient-specific pre-radiotherapeutic end-to-end verification devices in the Kingdom enabling comprehensive end-to-end verification of radiotherapy treatments, supporting accuracy, confidence, and patient safety from imaging and treatment planning through ...

ByRTsafe


SOPHiA Genetics and AstraZeneca Collaborate to Further Expand Global Access to Liquid Biopsy Testing

SOPHiA Genetics and AstraZeneca Collaborate to Further Expand Global Access to Liquid Biopsy Testing

By increasing availability of MSK-ACCESS® powered with SOPHiA DDM™, SOPHiA GENETICS and AstraZeneca aim to understand how liquid biopsy testing can complement solid tissue testing, and in some cases, provide greater benefit for labs and patients. This understanding will help support the case for broad global implementation. ...

BySOPHiA Genetics


SOPHiA Genetics Announces Validation of Novel Clinical Trial Assay Together with Precision for Medicine at World Clinical Biomarkers & CDx 2024

SOPHiA Genetics Announces Validation of Novel Clinical Trial Assay Together with Precision for Medicine at World Clinical Biomarkers & CDx 2024

Precision for Medicine incorporates scientific expertise and clinical trial excellence to deliver critical insights into patient biology. Precision is supporting the POTENTIATE clinical trial by adapting its diagnostic workflow to ensure a seamless connection with the SOPHiA DDM™ Platform. ...

BySOPHiA Genetics


Tempus Introduces New HER2 & FOLR1 Testing Solutions to Support Personalized Patient Care

Tempus Introduces New HER2 & FOLR1 Testing Solutions to Support Personalized Patient Care

Tempus, a leader in artificial intelligence and precision medicine, announced new testing solutions to help physicians identify patients with HER2 or FOLR1 expressing tumors, which may make such patients eligible for targeted therapies such as antibody–drug conjugates (ADCs). HER2 and FOLR1 testing by immunohistochemistry (IHC) is now available for all solid tumor cancers as an ...

ByTempus


Tempus Announces the Clinical Launch of its MRD Testing Portfolio

Tempus Announces the Clinical Launch of its MRD Testing Portfolio

NeXT Personal® Dx can detect small traces of ctDNA in the blood of patients with early non-small cell lung cancer (NSCLC) and breast cancer following curative intent treatment and can also be used for immunotherapy monitoring in late stage cancer across all solid tumors. The ultra-sensitive, personalized MRD assay identifies up to 1,800 somatic variants unique to a ...

ByTempus


Vantage Welcomes KEMP Hospice!

Vantage Welcomes KEMP Hospice!

We are thrilled to welcome KEMP Hospice to the growing community of amazing charities we work with across the UK. We are proud to provide the charity with our affordable and adaptable software solutions that support the outstanding care they provide to families and people living with life-limiting illnesses across their ...

ByVantage Software


Alfa Chemistry Recently Launched a Sub-website for Functional Polymers

Alfa Chemistry Recently Launched a Sub-website for Functional Polymers

Biomedical Polymers Biomedical polymers have and still continue to play an important role in how we support and treat patients with various diseases through their use in tissue and blood interacting medical devices and drug delivery systems. ...

ByAlfa Chemistry


Vantage Welcomes Saint Catherine’s Hospice!

Vantage Welcomes Saint Catherine’s Hospice!

We are delighted to welcome Saint Catherine’s Hospice Scarborough to the growing community of amazing hospice charities we work with across the UK. We are proud to provide Saint Catherine’s with our affordable and adaptable software solutions that support the outstanding care they provide to people with life-limiting ...

ByVantage Software


Vantage Welcomes St Luke’s Hospice!

Vantage Welcomes St Luke’s Hospice!

We are delighted to welcome St Luke’s Hospice to the growing community of amazing hospice charities we work with across the UK. We are proud to provide St Luke’s with our affordable and adaptable software solutions that support the outstanding care they provide to people living with life-limiting illnesses. ...

ByVantage Software


Anuncia Medical Announces the First Successful US Implant of the Company’s Newly Commercially Released ReFlow Mini Flusher Device for Hydrocephalus Patients

Anuncia Medical Announces the First Successful US Implant of the Company’s Newly Commercially Released ReFlow Mini Flusher Device for Hydrocephalus Patients

The second-generation, FDA-cleared ReFlow Mini Flusher is indicated for use in patients living with hydrocephalus or similar conditions. The reduced size and profile of the technology is designed to better support a broader hydrocephalus patient population, from infants to older adults. ...

ByAnuncia Medical, Inc.


Aflibercept 8 mg in diabetic macular edema first to achieve sustained vision gains with up to 83% of patients extended to 16-24 weeks at two years

Aflibercept 8 mg in diabetic macular edema first to achieve sustained vision gains with up to 83% of patients extended to 16-24 weeks at two years

“These clinically important results show that the burden of disease can be reduced for many more patients in the future contributing to improved adherence and thus better patient outcomes.” “Diabetic macular edema is a leading cause of vision loss, and we are fully committed to support patients with extended ...

ByBayer AG


Is HIFU ultrasound treatment safe

Is HIFU ultrasound treatment safe

They are more in need of remodelling of the skeletal support structure. Pregnant women, patients with severe heart disease and diabetes, such people should be guided by their doctor in choosing a suitable beauty solution. ...

ByBvlaser Bestview Medical and Beauty Equipment Co., Ltd


Daxor Corporation Announces Significant Expansion With Five Hospitals Implementing Its BVA-100 Blood Volume Diagnostic for Heart Failure Patients

Daxor Corporation Announces Significant Expansion With Five Hospitals Implementing Its BVA-100 Blood Volume Diagnostic for Heart Failure Patients

A third site is an academic medical center and is recognized as one of the top heart failure centers in the U.S. with more than 800 physicians in 200 specialties serving patients in Virginia. The site in Mississippi is a community-based facility providing care to patients in five counties in northeast Mississippi and three counties in southern Tennessee, while ...

ByDaxor Corporation


New real world study data on reduced risk of adverse kidney outcomes for Xarelto compared to VKA

New real world study data on reduced risk of adverse kidney outcomes for Xarelto compared to VKA

The study adds to the evidence obtained in the randomized controlled ROCKET-AF study and supports the use of Xarelto in this patient group, including the cautious use for patients with CKD stage 4 (the use of Xarelto is not recommended in patients with creatinine clearance < 15 ml/min). ...

ByBayer AG


Bayer driving innovation in radiology with new research across the portfolio presented at ECR

Bayer driving innovation in radiology with new research across the portfolio presented at ECR

In addition, Bayer’s Radiology team will present the launch of the MEDRADTM MRXperion MR Multi-Patient Disposable Kit, which can be utilized for multiple patients for up to 24 hours. The Multi-Patient Kit provides customers with the option to reduce time to change and refill syringes in between patients, thereby improving ...

ByBayer AG


Lifespin Announces Expansion of Laboratory Testing Capability

Lifespin Announces Expansion of Laboratory Testing Capability

Lifespin GmbH, based in Regensburg (Germany), with offices in Boston, Massachusetts, announced today that it has installed additional Nuclear Magnetic Resonance (NMR) equipment which will double Lifespin’s annual laboratory testing capacity. Lifespin will now be able to scan and create the corresponding digitized, quantitative metabolic profiles involving as many as 300,000 human samples ...

ByLifespin GmbH


History of Health Technologies and Meaningful Change in the Era of Health 4.0

History of Health Technologies and Meaningful Change in the Era of Health 4.0

Dr. Ali Tinazli's post at the Forbes magazine about "History Of Health Technologies And Meaningful Change In The Era Of Health 4.0" The medicine in ancient Egypt is some of the oldest in history. Although rudimentary, it was already highly personalized and with exclusive access. During the Renaissance—one of the most remarkable ages of humankind—medicine ...

ByLifespin GmbH


Bayer completes acquisition of Blackford Analysis Ltd.

Bayer completes acquisition of Blackford Analysis Ltd.

About Radiology at Bayer As a true life-science company with a heritage of over 100 years in Radiology, Bayer is committed to providing excellence, from innovative products to high-quality services, to support efficient and optimized patient care. Bayer offers a leading portfolio of contrast media for computed tomography (CT), X-Ray, and magnetic resonance ...

ByBayer AG


Guidelines for the diagnosis, treatment and metaphylaxis of urolithiasis

Guidelines for the diagnosis, treatment and metaphylaxis of urolithiasis

The new guideline is intended to provide support for the treatment of patients with urolithiasis in hospital and private practice settings. ...

ByFARCO-PHARMA GmbH


Stemline Therapeutics, a subsidiary of Menarini Group, Receives U.S. FDA Approval for ORSERDU (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer

Stemline Therapeutics, a subsidiary of Menarini Group, Receives U.S. FDA Approval for ORSERDU (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer

Stemline ARC, a patient support program is available to help guide eligible patients through the various aspects of getting started on treatment, from providing educational information to helping them understand their insurance coverage and identifying potential financial assistance options. For more information, patients and ...

ByThe Menarini Group

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical Equipment & Supplies
  • Medical Software
  • Medical Training Courses
  • Medical Industry Services
  • Medical Product Applications

Latest

  • Medical Industry News
  • Medical Industry Events

Publications

  • Medical Industry Articles & Case Studies
  • Medical Industry Books and Publications
  • Medical Industry Journals and Magazines
  • Medical Industry Downloads
  • Medical Industry Videos

Companies

  • Medical Industry Suppliers & Manufacturers

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT